Cancer patients face a high risk of venous thromboembolism and present unique treatment challenges due to elevated risks of both recurrence and bleeding.
Answers are grounded in this paper and cite their sources.
May warrant tailored anticoagulation strategies in cancer-associated VTE; leaves open optimal regimens balancing recurrence and bleeding risks.
Venous thromboembolism is a frequent complication in cancer patients and represents an important cause of morbidity and mortality. The risk of thrombosis depends on the specific type of malignancy and the presence of distant metastases. Furthermore, chemotherapeutic regimens and hormonal therapy as well as surgery and hospitalisation are associated with an increased rate of thromboembolism. The pathogenesis of the hypercoagulable state of malignancy involves the activation of endothelial cells and the release of tumour-associated procoagulants (tissue factor) and cytokines. Tumours can lead to uncommon sites of thrombosis by external compression of vessels and vascular invasion. Thrombosis of the hepatic vein or portal vein may be associated with myeloproliferative disorders. Due to the higher risk of thrombosis, hospitalised cancer patients should receive sufficient thromboprophylaxis. The treatment of venous thromboembolism in cancer patients is more challenging compared to the general medical population, as cancer patients have an increased risk of recurrent thrombosis, and of bleeding complications, especially in advanced cancer.
No takes yet. Share an insight, caveat, or question.
Hart et al. (2009) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: